Reverse Your Reliance on 503Bs for Compounded Sterile Products

The Future of Pharmacy, presented by Omnicell

Вміст надано Omnicell. Весь вміст подкастів, включаючи епізоди, графіку та описи подкастів, завантажується та надається безпосередньо компанією Omnicell або його партнером по платформі подкастів. Якщо ви вважаєте, що хтось використовує ваш захищений авторським правом твір без вашого дозволу, ви можете виконати процедуру, описану тут https://uk.player.fm/legal.

2+ y ago 33:03

MP3•Головна епізоду

Health systems are continuously being challenged to ensure IV preparations are prepared safely and accurately while complying with increasingly complex regulations. As a result, many rely on 503B outsourcing pharmacies to provide the vast majority of their pre-mixed compounded sterile products. But as product shortages and pricing fluctuations in the supply chain become more acute, rather than provide relief, 503Bs actually can put more pressure on pharmacy staffs and budget.

Joining host Ken Perez to discuss are pharmacy leaders who met those challenges by going against the trend – by insourcing their sterile compounding, with a twist.

Joseph J. DiCubellis, RPh, MPH, Senior Director of Pharmacy Services for the University of Maryland Medical System and Senior Director of Pharmacy, University of Maryland Medical Center
Yevgeniya Kogan-Hardesty, PharmD, BCSCP, Sterile Compounding, Pharmacy Manager, University of Maryland Medical Center

23 епізодів

#Tech #Fitness #Business #Omnicell #Healthcare #Healthtech #Pharmacy #Technology #Drug Costs #Prescription Drugs #Medical